Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Bendamustine demonstrates a favorable safety profile in lymphoma chemotherapy.
• Chronic lymphocytic leukemia (CLL) treatment often involves chemotherapy and stem cell transplantation.

Purpose of the Study:

• To evaluate the long-term impact of adding bendamustine to conditioning regimens for allogeneic stem cell transplantation (alloSCT) in CLL patients.
• To compare outcomes including survival, engraftment, immune recovery, and graft-versus-host disease (GvHD) with the fludarabine, cyclophosphamide, and rituximab (FCR) regimen.

Main Methods:

• Retrospective analysis of 89 CLL patients from three institutional trials.
• Comparison of patients receiving bendamustine, fludarabine, and rituximab (BFR) versus FCR conditioning regimens.

Main Results:

• The bendamustine, fludarabine, and rituximab (BFR) group showed significantly higher 3-year overall survival (82% vs 51%) and progression-free survival (PFS) (63% vs 27%) compared to the FCR group.
• Fewer BFR-treated patients experienced severe neutropenia (38% vs 3%).
• The BFR regimen was associated with lower treatment-related mortality (8% vs 23%) and a reduced incidence of severe GvHD (4% vs 10%).

Conclusions:

• Addition of bendamustine to alloSCT conditioning for CLL patients is linked to improved survival and reduced mortality.
• Bendamustine-containing regimens may lead to less myelosuppression and lower rates of GvHD in CLL alloSCT.
• This study provides evidence for bendamustine's benefit in CLL alloSCT conditioning.